149 related articles for article (PubMed ID: 32938997)
1. Attenuating hypoxia driven malignant behavior in glioblastoma with a novel hypoxia-inducible factor 2 alpha inhibitor.
Renfrow JJ; Soike MH; West JL; Ramkissoon SH; Metheny-Barlow L; Mott RT; Kittel CA; D'Agostino RB; Tatter SB; Laxton AW; Frenkel MB; Hawkins GA; Herpai D; Sanders S; Sarkaria JN; Lesser GJ; Debinski W; Strowd RE
Sci Rep; 2020 Sep; 10(1):15195. PubMed ID: 32938997
[TBL] [Abstract][Full Text] [Related]
2. ARNT-dependent HIF-2 transcriptional activity is not sufficient to regulate downstream target genes in neuroblastoma.
Persson CU; von Stedingk K; Fredlund E; Bexell D; Påhlman S; Wigerup C; Mohlin S
Exp Cell Res; 2020 Mar; 388(2):111845. PubMed ID: 31945318
[TBL] [Abstract][Full Text] [Related]
3. Differential effects of HIF2α antagonist and HIF2α silencing in renal cancer and sensitivity to repurposed drugs.
Arnaiz E; Miar A; Bridges E; Prasad N; Hatch SB; Ebner D; Lawrie CH; Harris AL
BMC Cancer; 2021 Aug; 21(1):896. PubMed ID: 34353313
[TBL] [Abstract][Full Text] [Related]
4. Hypoxia-inducible factor 2α: a novel target in gliomas.
Renfrow JJ; Soike MH; Debinski W; Ramkissoon SH; Mott RT; Frenkel MB; Sarkaria JN; Lesser GJ; Strowd RE
Future Med Chem; 2018 Sep; 10(18):2227-2236. PubMed ID: 30089425
[TBL] [Abstract][Full Text] [Related]
5. PHGDH as a Key Enzyme for Serine Biosynthesis in HIF2α-Targeting Therapy for Renal Cell Carcinoma.
Yoshino H; Nohata N; Miyamoto K; Yonemori M; Sakaguchi T; Sugita S; Itesako T; Kofuji S; Nakagawa M; Dahiya R; Enokida H
Cancer Res; 2017 Nov; 77(22):6321-6329. PubMed ID: 28951458
[TBL] [Abstract][Full Text] [Related]
6. 3-[(1
Xu R; Wang K; Rizzi JP; Huang H; Grina JA; Schlachter ST; Wang B; Wehn PM; Yang H; Dixon DD; Czerwinski RM; Du X; Ged EL; Han G; Tan H; Wong T; Xie S; Josey JA; Wallace EM
J Med Chem; 2019 Aug; 62(15):6876-6893. PubMed ID: 31282155
[TBL] [Abstract][Full Text] [Related]
7. HIF-2 Complex Dissociation, Target Inhibition, and Acquired Resistance with PT2385, a First-in-Class HIF-2 Inhibitor, in Patients with Clear Cell Renal Cell Carcinoma.
Courtney KD; Ma Y; Diaz de Leon A; Christie A; Xie Z; Woolford L; Singla N; Joyce A; Hill H; Madhuranthakam AJ; Yuan Q; Xi Y; Zhang Y; Chang J; Fatunde O; Arriaga Y; Frankel AE; Kalva S; Zhang S; McKenzie T; Reig Torras O; Figlin RA; Rini BI; McKay RM; Kapur P; Wang T; Pedrosa I; Brugarolas J
Clin Cancer Res; 2020 Feb; 26(4):793-803. PubMed ID: 31727677
[TBL] [Abstract][Full Text] [Related]
8. Activity of a first-in-class oral HIF2-alpha inhibitor, PT2385, in patients with first recurrence of glioblastoma.
Strowd R; Ellingson B; Raymond C; Yao J; Wen PY; Ahluwalia M; Piotrowski A; Desai A; Clarke JL; Lieberman FS; Desideri S; Nabors LB; Ye X; Grossman S
J Neurooncol; 2023 Oct; 165(1):101-112. PubMed ID: 37864646
[TBL] [Abstract][Full Text] [Related]
9. A Small-Molecule Antagonist of HIF2α Is Efficacious in Preclinical Models of Renal Cell Carcinoma.
Wallace EM; Rizzi JP; Han G; Wehn PM; Cao Z; Du X; Cheng T; Czerwinski RM; Dixon DD; Goggin BS; Grina JA; Halfmann MM; Maddie MA; Olive SR; Schlachter ST; Tan H; Wang B; Wang K; Xie S; Xu R; Yang H; Josey JA
Cancer Res; 2016 Sep; 76(18):5491-500. PubMed ID: 27635045
[TBL] [Abstract][Full Text] [Related]
10. The HIF1α/HIF2α-miR210-3p network regulates glioblastoma cell proliferation, dedifferentiation and chemoresistance through EGF under hypoxic conditions.
Wang P; Yan Q; Liao B; Zhao L; Xiong S; Wang J; Zou D; Pan J; Wu L; Deng Y; Wu N; Gong S
Cell Death Dis; 2020 Nov; 11(11):992. PubMed ID: 33208727
[TBL] [Abstract][Full Text] [Related]
11. Targeting PDGFRα-activated glioblastoma through specific inhibition of SHP-2-mediated signaling.
Sang Y; Hou Y; Cheng R; Zheng L; Alvarez AA; Hu B; Cheng SY; Zhang W; Li Y; Feng H
Neuro Oncol; 2019 Nov; 21(11):1423-1435. PubMed ID: 31232447
[TBL] [Abstract][Full Text] [Related]
12. Riluzole enhances the antitumor effects of temozolomide via suppression of MGMT expression in glioblastoma.
Yamada T; Tsuji S; Nakamura S; Egashira Y; Shimazawa M; Nakayama N; Yano H; Iwama T; Hara H
J Neurosurg; 2020 Mar; 134(3):701-710. PubMed ID: 32168477
[TBL] [Abstract][Full Text] [Related]
13. Targeting renal cell carcinoma with a HIF-2 antagonist.
Chen W; Hill H; Christie A; Kim MS; Holloman E; Pavia-Jimenez A; Homayoun F; Ma Y; Patel N; Yell P; Hao G; Yousuf Q; Joyce A; Pedrosa I; Geiger H; Zhang H; Chang J; Gardner KH; Bruick RK; Reeves C; Hwang TH; Courtney K; Frenkel E; Sun X; Zojwalla N; Wong T; Rizzi JP; Wallace EM; Josey JA; Xie Y; Xie XJ; Kapur P; McKay RM; Brugarolas J
Nature; 2016 Nov; 539(7627):112-117. PubMed ID: 27595394
[TBL] [Abstract][Full Text] [Related]
14. Cordycepin Augments the Chemosensitivity of Human Glioma Cells to Temozolomide by Activating AMPK and Inhibiting the AKT Signaling Pathway.
Bi Y; Li H; Yi D; Sun Y; Bai Y; Zhong S; Song Y; Zhao G; Chen Y
Mol Pharm; 2018 Nov; 15(11):4912-4925. PubMed ID: 30336060
[TBL] [Abstract][Full Text] [Related]
15. Combined acetyl-11-keto-β-boswellic acid and radiation treatment inhibited glioblastoma tumor cells.
Conti S; Vexler A; Edry-Botzer L; Kalich-Philosoph L; Corn BW; Shtraus N; Meir Y; Hagoel L; Shtabsky A; Marmor S; Earon G; Lev-Ari S
PLoS One; 2018; 13(7):e0198627. PubMed ID: 29969452
[TBL] [Abstract][Full Text] [Related]
16. Targeting HIF2α in Clear-Cell Renal Cell Carcinoma.
Ricketts CJ; Crooks DR; Linehan WM
Cancer Cell; 2016 Oct; 30(4):515-517. PubMed ID: 27728802
[TBL] [Abstract][Full Text] [Related]
17. IKBKE enhances TMZ-chemoresistance through upregulation of MGMT expression in glioblastoma.
Guo G; Sun Y; Hong R; Xiong J; Lu Y; Liu Y; Lu J; Zhang Z; Guo C; Nan Y; Huang Q
Clin Transl Oncol; 2020 Aug; 22(8):1252-1262. PubMed ID: 31865606
[TBL] [Abstract][Full Text] [Related]
18. Metabolic Profiling of the Novel Hypoxia-Inducible Factor 2
Xie C; Gao X; Sun D; Zhang Y; Krausz KW; Qin X; Gonzalez FJ
Drug Metab Dispos; 2018 Apr; 46(4):336-345. PubMed ID: 29363499
[TBL] [Abstract][Full Text] [Related]
19. Interference with PSMB4 Expression Exerts an Anti-Tumor Effect by Decreasing the Invasion and Proliferation of Human Glioblastoma Cells.
Cheng YC; Tsai WC; Sung YC; Chang HH; Chen Y
Cell Physiol Biochem; 2018; 45(2):819-831. PubMed ID: 29414809
[TBL] [Abstract][Full Text] [Related]
20. Anticancer drug candidate CBL0137, which inhibits histone chaperone FACT, is efficacious in preclinical orthotopic models of temozolomide-responsive and -resistant glioblastoma.
Barone TA; Burkhart CA; Safina A; Haderski G; Gurova KV; Purmal AA; Gudkov AV; Plunkett RJ
Neuro Oncol; 2017 Feb; 19(2):186-196. PubMed ID: 27370399
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]